UN
Unicycive Therapeutics, Inc.
UNCY · NASDAQ
$5.16 -1.53% (-$0.08)
1M +1.78%
Market Cap $141.5M
P/E Ratio -
Div. Yield -
ROE 88.81%
Bulios Fair Price
$4.53
12.2% downside
Current Price
$5.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, UNCY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
72 /100
Cheap P/B 2.66x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 61.44%
ROE 88.81%
ROA 48.90%
Debt
69 /100
Low Debt/Equity 0.01x
Current ratio 3.81x
Int. coverage -837.67x
Stability
5 /100
Unstable Beta 1.78x
EPS volatility 216.62%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about UNCY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Shalabh K. Gupta
Employees
21
Headquarters
Mountain View
Upcoming events
11 NOV
Earnings
Upcoming earnings report